February 2, 2015 | OPKO Health announced that it will submit a request to begin clinical trials on a drug for the treatment of hemophilia. If the drug is approved, it will directly enter into Phase II clinical trials. It is similar technologically to another of the company’s drug platforms and is also meant to treat hemophilia, a genetic disease in which blood fails to clot. The latest OPKO drug is meant to reduce the number of injections that hemophiliacs must receive. OPKO is headquartered in Florida, but operates in Israel, Mexico, Uruguay and Spain.